Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | June 05, 2026 | June 09, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Sr. VP Fince-Global Controller | May 03, 2023 | May 05, 2023 |
| Organon & Co.OGN · Entity 4115 | Director | May 07, 2021 | May 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 30,000 · Balance 30,000 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2036-06-05 | Direct | 60,000 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 60,000 · Balance 60,000 F2: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
F2: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
Merck & Co., Inc.
Report date May 03, 2023 · Filed May 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,709.972 |
Ending reported balance
After 2023-05-04 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2023-05-03 · Exercise / conversion · Acquired 803 · Balance 45,362.972 Row 2 · 2023-05-03 · Tax withholding · Disposed 276 · Balance 45,086.972 Row 3 · 2023-05-04 · Exercise / conversion · Acquired 949 · Balance 46,035.972 Row 4 · 2023-05-04 · Tax withholding · Disposed 326 · Balance 45,709.972 Row 5 · 2023-05-04 · Exercise / conversion · Acquired 15,875 · Balance 61,584.972 Row 6 · 2023-05-04 · Sale · Disposed 15,875 · Balance 45,709.972 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.5000 to $117.6200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2025-05-03 | Direct | 1,608 |
Reported balance
After 2023-05-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-05-03 · Exercise / conversion · Disposed 803 · Balance 1,608 F2: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2024-05-04 | Direct | 951 |
Reported balance
After 2023-05-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-05-04 · Exercise / conversion · Disposed 949 · Balance 951 F2: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.07 · Expires 2027-05-04 | Direct | 0 |
Reported balance
After 2023-05-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-05-04 · Exercise / conversion · Disposed 15,875 · Balance 0 F5: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.5000 to $117.6200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F3: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025.
F4: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.
F5: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.
Organon & Co.
Report date May 07, 2021 · Filed May 07, 2021
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 22:43 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001610717-26-000205 · form4.xml · derivative · entry 2 Karachun Rita A · CIK 0001601572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-06-05 F2 · derivative.exercise_date: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 22:43 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000205 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 22:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001610717-25-000225 · form4.xml · derivative · entry 1 Karachun Rita A · CIK 0001601572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 11, 2025, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 22:57 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 168,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001610717-24-000295 · form4.xml · derivative · entry 1 Karachun Rita A · CIK 0001601572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,000 Underlying: Common Stock · 168,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/3rd of the total number of shares on the one year anniversary of June 4, 2024 and 1/36th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,875 | $0.00 Strike: $62.07 | $0.00 |
DisclosureSEC source: 0001127602-23-014739 · form4.xml · derivative · entry 9 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,875 shares Expires 2027-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 949 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014739 · form4.xml · derivative · entry 8 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 951 Underlying: Common Stock · 949 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 15,875 | $117.53 | $1,865,842.73 |
DisclosureSEC source: 0001127602-23-014739 · form4.xml · nonDerivative · entry 6 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,709.972 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.5000 to $117.6200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 15,875 | $62.07 | $985,361.25 |
DisclosureSEC source: 0001127602-23-014739 · form4.xml · nonDerivative · entry 5 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,584.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 326 | $118.22 | $38,539.72 |
DisclosureSEC source: 0001127602-23-014739 · form4.xml · nonDerivative · entry 4 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,709.972 Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 949 | $118.22 | $112,190.78 |
DisclosureSEC source: 0001127602-23-014739 · form4.xml · nonDerivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,035.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 803 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014739 · form4.xml · derivative · entry 7 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,608 Underlying: Common Stock · 803 shares Expires 2025-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 276 | $117.89 | $32,537.64 |
DisclosureSEC source: 0001127602-23-014739 · form4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,086.972 Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 803 | $117.89 | $94,665.67 |
DisclosureSEC source: 0001127602-23-014739 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,362.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 1,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014578 · form4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,781 Underlying: Common Stock · 1,781 shares Expires 2026-05-02 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 9,682 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014578 · form4.xml · derivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,682 Underlying: Common Stock · 9,682 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:24 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 930 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014272 · form4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 930 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:24 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 319 | $115.47 | $36,834.93 |
DisclosureSEC source: 0001127602-23-014272 · form4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,559.972 Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:24 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 930 | $115.47 | $107,387.10 |
DisclosureSEC source: 0001127602-23-014272 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,878.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:26 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 2,846 | $109.88 | $312,718.48 |
DisclosureSEC source: 0001127602-23-002247 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,948.972 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $62.07 | $0.00 |
DisclosureSEC source: 0001127602-22-024608 · form4.xml · derivative · entry 5 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,875 Underlying: Common Stock · 15,000 shares Expires 2027-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. F4 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,997 | $0.00 Strike: $53.06 | $0.00 |
DisclosureSEC source: 0001127602-22-024608 · form4.xml · derivative · entry 4 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,997 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 31,997 | $100.34 | $3,210,684.57 |
DisclosureSEC source: 0001127602-22-024608 · form4.xml · nonDerivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,102.972 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.2800 to $100.4700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024608 · form4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,099.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 16,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024608 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,099.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 949 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013535 · form4.xml · derivative · entry 5 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Underlying: Common Stock · 949 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F5 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F6 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. F5 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 326 | $87.10 | $28,394.60 |
DisclosureSEC source: 0001127602-22-013535 · form4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,102.972 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 949 | $87.10 | $82,657.90 |
DisclosureSEC source: 0001127602-22-013535 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,428.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 902 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013254 · form4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 902 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 309 | $87.65 | $27,083.85 |
DisclosureSEC source: 0001127602-22-013254 · form4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,479.972 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 902 | $87.65 | $79,060.30 |
DisclosureSEC source: 0001127602-22-013254 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,788.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 2,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013535 · form4.xml · derivative · entry 4 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,411 Underlying: Common Stock · 2,411 shares Expires 2025-05-03 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 13,592 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013535 · form4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,592 Underlying: Common Stock · 13,592 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 928 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013024 · form4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930 Underlying: Common Stock · 928 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 318 | $88.69 | $28,203.42 |
DisclosureSEC source: 0001127602-22-013024 · form4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,886.972 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 928 | $88.69 | $82,304.32 |
DisclosureSEC source: 0001127602-22-013024 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,204.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 3,478 | $73.51 | $255,667.78 |
DisclosureSEC source: 0001127602-22-007013 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,276.972 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $53.06 | $0.00 |
DisclosureSEC source: 0001127602-21-028387 · form4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,997 Underlying: Common Stock · 25,000 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 25,000 | $88.45 | $2,211,215.00 |
DisclosureSEC source: 0001127602-21-028387 · form4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,798.972 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.4200 to $88.5400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028387 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,798.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 6, 2021 21:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 1,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015768 · form4.xml · derivative · entry 5 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,212 shares Expires 2021-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F5 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2021 Filed May 6, 2021 21:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 2,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015768 · form4.xml · derivative · entry 4 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,764 Underlying: Common Stock · 2,764 shares Expires 2024-05-04 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2021 Filed May 6, 2021 21:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 21,429 | $0.00 Strike: $75.99 | $0.00 |
DisclosureSEC source: 0001127602-21-015768 · form4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,429 Underlying: Common Stock · 21,429 shares Expires 2031-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2021 Filed May 6, 2021 21:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 416 | $75.98 | $31,607.68 |
DisclosureSEC source: 0001127602-21-015768 · form4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,798.972 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2021 Filed May 6, 2021 21:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,212 | $75.98 | $92,087.76 |
DisclosureSEC source: 0001127602-21-015768 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,214.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 875 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015234 · form4.xml · derivative · entry 6 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875 Underlying: Common Stock · 875 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 300 | $74.50 | $22,350.00 |
DisclosureSEC source: 0001127602-21-015234 · form4.xml · nonDerivative · entry 4 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,002.972 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 875 | $74.50 | $65,187.50 |
DisclosureSEC source: 0001127602-21-015234 · form4.xml · nonDerivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,302.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 901 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015234 · form4.xml · derivative · entry 5 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,803 Underlying: Common Stock · 901 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 309 | $74.50 | $23,020.50 |
DisclosureSEC source: 0001127602-21-015234 · form4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,427.972 Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 901 | $74.50 | $67,124.50 |
DisclosureSEC source: 0001127602-21-015234 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,736.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.